Slide 1: Corporate Presentation
EF LABS: CORPORATE PRESENTATION
Slide 2: Disclaimer
DISCLAIMER CONFIDENTIALITY INFORMATIONS GENERAL CONDITIONS This Document has been The Document does not Although care and diligence drafted by Cube Labs S.p.A. represent in its entirety either has been taken in the (hereinafter the “Company”) the Company or the project preparation of the Document, s
Slide 3: Index
INDEX 1 COMPANY OVERVIEW p. 4 2 BUSINESS MODEL p. 17 3 START-UP PORTFOLIO p. 21 4 MARKET p. 24 5 FINANCIAL RESULTS p. 26 6 TEAM p. 29 7 STRATEGIC ADVISORY BOARD p. 33
Slide 4: Company Overview
COMPANY 1 OVERVIEW
Slide 5: Cube Labs at a Glance
CUBE LABS AT A GLANCE Cube Labs S.p.A. is an Italian Venture Builder specialized in the development of projects in the healthcare technologies sector. Cube Labs has been listed since March 21, 2023 on Euronext Growth Milan - Professional segment, dedicated to SMEs with high growth potential. 3 offic
Slide 6: Portfolio
PORTFOLIO 15 start-ups 1 9 24 700 exclusive universities licenses in INBB network2 researchers in INBB 52 network 2 patents 88 research centers in CNR network3 1. Including 2 newly established start-ups (Myrtoviva and Regenerabioma). 2. www.inbb.it/chi-siamo/universita-aderenti. 3. www.cnr.it/en/cnr
Slide 7: Key Financials 1H 2023
KEY FINANCIALS 1H 2023 1.3M€ 752 K€ revenues 52 .3M€ portfolio PFN value* (211K€) EBITDA (321K€) net profit * To determine the value of its portfolio, the Company engaged Pirola Pennuto Zei e Associati to prepare a specialized sworn appraisal report. The Board of Directors also commissioned Venture
Slide 8: IPO EGM-PRO
IPO EGM-PRO Number of shares pre-IPO 15,000,000 Shares newly issued 2,052,500 Warrant after conversion (20/10/2023) 1,752,500 Outstanding shares post-IPO* 17,852,500 Free Float 15.98% IPO Date 21 March 2023 Issue Price (€) 2.00 Market Cap (€/M) @ IPO 34.105 Market EGM PRO Title update YoY to 17/05/2
Slide 9: EGM-PRO Performance
EGM-PRO PERFORMANCE Volume Close 2,2 150K 2,12 2,13 2,11 2,16 2,07 2,11 2,1 2,0 2,00 Close (€) 100K Volume 1,9 1,8 50K 1,7 1,6 1,50 0K 1,5 Mar 2023 May 2023 Jul 2023 Sep 2023 Nov 2023 Jan 2024 Mar 2024 May 2024 Date Average Volume* 2023 Total Volume 2023 Total Volume Average Volume* 2024 Total Volum
Slide 10: EGM-PRO Benchmark
EGM-PRO BENCHMARK NAME SYMBOL INDUSTRY YEAR MARKET CAP MTD PERF. YTD PERF. E-NOVIA E9IA Financials 2022 € 150,850,661 0.0% 0.0% HOMIZY HZY Consumer Discretionary 2021 € 48,369,201 0.0% 0.0% CUBE LABS CUBE Financials 2023 € 38,561,400 6.9% 1.4% CREACTIVES GROUP CREG Technology 2023 € 33,674,401 0.0%
Slide 11: Governance and Shareholding
GOVERNANCE AND SHAREHOLDING BOARD OF DIRECTORS Filippo Surace Chairman and CEO Renato Del Grosso Massimo Fiocchi Member of Board Member of Board Domenico Colella Mario Matteo Busso Non-executive Director Indipendent Director AUDITING FIRM BOARD OF STATUTORY AUDITORS F. Surace* P. Ragni Market Others
Slide 12: 2023: Our Footprint
2023: OUR FOOTPRINT MARCH OCTOBER DECEMBER IPO on Euronext Growth Cube Labs shortlisted for Cube Labs expands portfolio: Milano – Professional Prix Galien USA “Incubators, two new startups founded segment. Accelerators, Equity” category. in nutraceutical and MedTech fields. Conversion of 250.000 war
Slide 13: Key Success Factors
KEY SUCCESS FACTORS FIRST MOVER SUCCESSFUL TEAM HIGH DEGREE OF CONTROL Experts with international Cube Labs is the first venture experience in both industry- builder in healthcare sector, From the initial stages leading companies and listed on EGM – Professional to the commercialization top academic
Slide 14: Business Model
BUSINESS MODEL First venture builder in the healthcare technology space in Italy. We build companies from promising, early-stage R&D, to transform pioneering science into healthcare solutions. BUILDING We source proprietary science to build promising healthcare technology companies from scratch. FIN
Slide 15: Business Plan
BUSINESS PLAN SHORT TERM STRATEGY MID-LONG TERM STRATEGY VALORIZATION OF THE SUBSIDIARY R&D ACTIVITIES ON ADDITIONAL COMPANIES BY INCREASING R&D INITIATIVES ALREADY IN THE PORTFOLIO ACTIVITY ON SELECTED INITIATIVES CORPORATE FINANCE & Cube Labs intends to increase its COMMERCIAL OPERATIONS R&D activ
Slide 16: Accelerating ESG Impact
ACCELERATING ESG IMPACT DEMOCRATIZATION ACCESSIBILITY A HEALTHIER FUTURE Pervasive knowledge as a Life Sciences accessible to all. Our ESG approach for a healthier widespread economic advantage. Our vision, our tangible future. Promoting innovation The technology transfer through commitment. and sup
Slide 17: Business Model
BUSINESS 2 MODEL
Slide 18: Business Model
BUSINESS MODEL Cube Labs is a shareholder of subsidiaries that hold academic research projects that have passed the Proof of Concept (PoC), and that come mainly from the partnership with INBB. The Company selects academic projects with high development potential. A key point of Cube Labs’ business m
Slide 19: Our Focus Areas
OUR FOCUS AREAS The Company prefers a B2B focus, supporting the subsidiary companies in the development of their R&D pipeline to the Corporate market. Cube Labs mainly participates as a shareholder in the following areas and at certain stages of project development: PHARMACEUTICALS BIOTECH NUTRACEUT
Slide 20: Revenue Model
REVENUE MODEL For the services (strategic, operational and financial support) provided by the Company, the subsidiaries pay a fee to Cube Labs. The Company also realises a capital gain at the time of exit from the investee. SERVICE ROYALTY FUNDRAISING EXIT FEE FEE FEE FEE e.g. International Commerci
Slide 21: Start-up Portfolio
START-UP 3 PORTFOLIO
Slide 22: Start-up Portfolio
START-UP PORTFOLIO PHARMACEUTICALS PHARMACEUTICALS PHARMACEUTICALS BIOTECH Regenerative Solutions for the Research and Solutions for the technologies against treatment of rare development of treatment of complex osteoarthritis and diseases, which occur therapeutic molecules, wounds or chronic relate
Slide 23: Start-up Portfolio
START-UP PORTFOLIO MEDTECH MEDTECH MEDTECH MEDTECH Technologies for Development of Development of Development of the improvement of technologies for bio-compatible bio-sensors for absorbent products endovascular robotics. hydrogels for dentistry, diagnostic, veterinary, (e. g. diapers), with the der
Slide 24: Market
lanavw "7
Slide 25: Life Science Market in Italy
LIFE SCIENCE MARKET IN ITALY PHARMA & BIOTECH Italy in 2022 ranked 3rd in Europe for pharmaceutical and medical product exports (USD 49 MLD)1; 822 biotech companies of which 312 dedicated to research of which 292 are Italian-controlled; 29.6% innovative start-ups2; 90% share of pharmaceutical export
Slide 26: Financial Results
FINANCIAL 5 RESULTS
Slide 27: Balance Sheet
BALANCE SHEET Balance sheet (€/000) FY 2019 FY 2020 FY 2021 FY 2022 1H 2023 Intangible asset 10 9 15 344 1,149 Tangible asset 2 2 3 2 2 Financial asset 349 51,744 52,108 52,312 52,320 LT asset 361 51,755 52,126 52,657 53,471 Other non-current assets - - - 53 97 Net working capital 1,631 2,402 2,122
Slide 28: Income Statement
INCOME STATEMENT Income statement (€/000) FY 2019 FY 2020 FY 2021 FY 2022 Income statement (€/000) 1H 2022 1H 2023 Revenue 568 950 1,127 1,143 Revenues 533 752 Var YoY% +99.3% +67.3% +18.6% +1.42% Var YoY% +41.1% Raw materials (3) (2) (5) (3) Raw materials (2) (0.8) Services (230) (410) (571) (903)
Slide 29: Team
TEAM 6
Slide 30: Founders
FOUNDERS Filippo Surace Renato Del Grosso Massimo Fiocchi Founder & CEO Co-Founder & Co-Founder & Chief Strategy Officer Chief Financial Officer EDUCATION AND TRAINING EDUCATION AND TRAINING EDUCATION AND TRAINING KEY PROFESSIONAL EXPERIENCE KEY PROFESSIONAL EXPERIENCE KEY PROFESSIONAL EXPERIENCE 30
Slide 31: Executive Team Leaders
EXECUTIVE TEAM LEADERS Neil Thomas Chris Hentschel Chief Business Officer Chief Scientific Officer • Partner in Ventac Partners since 2012 with executive roles • Molecular biologist and Co-founder in their portfolio companies of The Ulysses Advisory Group • Previously Director of Business Developmen
Slide 32: Executive Team Leaders
EXECUTIVE TEAM LEADERS Paolo Occhialini Daria Brambilla Portfolio Manager Scientific Head of Venture Companies • Graduated with honors in Medicine and Surgery, he • Consolidated experience in biochemistry, molecular obtained a post-graduate master’s degree in “Organization biology, immunology and ce
Slide 33: Strategic Advisory Board
Guvod AdOsIAdV SIDSLVYLS Ls
Slide 34: Strategic Advisory Board
STRATEGIC ADVISORY BOARD Yossi Bornstein Adam Broncel Slawomir Chomik • Over 35 years in Israeli & International biomed industry • Co-founder and former GP, Biomed Venture Capital Fund • CEO and Founder of Shizim Group, ShizimXL (medical devices) and • Over 20 years experience in the pharmaceutical
Slide 35: Strategic Advisory Board
STRATEGIC ADVISORY BOARD Pierre A. Morgon Mikael Oerum Fintan Walton • 40 years of experience in the pharmaceutical, biotech and finance sectors • CEO and Founder, PharmaVentures, a premier transaction advisory • CEO of MRGN Advisors • Raised over USD 300M in equity and soft funding into biotech fir
Slide 36: Get in Touch
GET IN TOUCH Cube Labs S.p.A. Via G. Caccini, 1 00198 – Rome, Italy www.cube-labs.com info@cube-labs.com